Adaptive Evolution of a Tagged Chimeric Gammaretrovirus: Identification of Novel cis-Acting Elements that Modulate Splicing

Journal of Molecular Biology

Volumn 369, Issue 5, 2007, Pages 1214-1229

  Logg, Christopher R ^a   Baranick, Brian T ^a   Lemp, Nathan A ^a   Kasahara, Noriyuki ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

envelope; evolution; murine leukemia virus; retrovirus; splicing

Indexed keywords

CIS ACTING ELEMENT; GENOMIC RNA; RETROVIRUS VECTOR; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADAPTATION; AMINO ACID SUBSTITUTION; ARTICLE; ENVELOPE GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; GIBBON LEUKEMIA VIRUS; MOLECULAR EVOLUTION; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RNA REPLICATION; RNA SPLICING; TRANSGENE; VIRUS GENE; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION;

GAMMARETROVIRUS; GIBBON APE LEUKEMIA VIRUS; MURINE LEUKEMIA VIRUS;

EID: 34248677082     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.04.026     Document Type: Article

References (64)

1. Overbaugh J., Miller A.D., and Eiden M.V. Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol. Mol. Biol. Rev. 65 (2001) 371-389
2. Sanders D.A. No false start for novel pseudotyped vectors. Curr. Opin. Biotechnol. 13 (2002) 437-442
3. Mild M., Esbjornsson J., Fenyo E.M., and Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J. Virol. 81 (2007) 3369-3376
4. Roy-Burman P. Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Virus Genes 11 (1995) 147-161
5. Chen B.K., Rousso I., Shim S., and Kim P.S. Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. Proc. Natl Acad. Sci. USA 98 (2001) 15239-15244
6. Bray M., Prasad S., Dubay J.W., Hunter E., Jeang K.T., Rekosh D., and Hammarskjold M.L. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc. Natl Acad. Sci. USA 91 (1994) 1256-1260
7. Deminie C.A., and Emerman M. Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions. J. Virol. 67 (1993) 6499-6506
8. Nack U., and Schnierle B.S. Replacement of the murine leukemia virus (MLV) envelope gene with a truncated HIV envelope gene in MLV generates a virus with impaired replication capacity. Virology 315 (2003) 209-216
9. Owens C.M., Yang P.C., Gottlinger H., and Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J. Virol. 77 (2003) 726-731
10. Yamashita M., and Emerman M. The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog. 1 (2005) e18
11. Ambrose Z., Boltz V., Palmer S., Coffin J.M., Hughes S.H., and Kewalramani V.N. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78 (2004) 13553-13561
12. Poon D.T., Li G., and Aldovini A. Nucleocapsid and matrix protein contributions to selective human immunodeficiency virus type 1 genomic RNA packaging. J. Virol. 72 (1998) 1983-1993
13. Shikova-Lekova E., Lindemann D., Pietschmann T., Juretzek T., Rudolph W., Herchenroder O., et al. Replication-competent hybrids between murine leukemia virus and foamy virus. J. Virol. 77 (2003) 7677-7681
14. Logg C.R., Logg A., Matusik R.J., Bochner B.H., and Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 76 (2002) 12783-12791
15. Logg C.R., Logg A., Tai C.K., Cannon P.M., and Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J. Virol. 75 (2001) 6989-6998
16. Logg C.R., Tai C.K., Logg A., Anderson W.F., and Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther. 12 (2001) 921-932
17. Bunnell B.A., Kluge K.A., Lee-Lin S.Q., Byrne E.R., Orlic D., Metzger M.E., et al. Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells. Gene Ther. 6 (1999) 48-56
18. Horn P.A., Topp M.S., Morris J.C., Riddell S.R., and Kiem H.P. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 100 (2002) 3960-3967
19. Movassagh M., Boyer O., Burland M.C., Leclercq V., Klatzmann D., and Lemoine F.M. Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum. Gene Ther. 11 (2000) 1189-1200
20. Svarovskaia E.S., Cheslock S.R., Zhang W.H., Hu W.S., and Pathak V.K. Retroviral mutation rates and reverse transcriptase fidelity. Front. Biosci. 8 (2003) d117-d134
21. Barsov E.V., Payne W.S., and Hughes S.H. Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range. J. Virol. 75 (2001) 4973-4983
22. Marzio G., Verhoef K., Vink M., and Berkhout B. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl Acad. Sci. USA 98 (2001) 6342-6347
23. O'Reilly L., and Roth M.J. Second-site changes affect viability of amphotropic/ecotropic chimeric enveloped murine leukemia viruses. J. Virol. 74 (2000) 899-913
24. Bendtsen J.D., Nielsen H., von Heijne G., and Brunak S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340 (2004) 783-795
25. Swanstrom R., and Wills J.W. Synthesis, assembly, and processing of viral proteins. In: Coffin J.M., Hughes S.H., and Varmus H. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press, Plainview, NY 263-334
26. Lazo P.A., Prasad V., and Tsichlis P.N. Splice acceptor site for the env message of Moloney murine leukemia virus. J. Virol. 61 (1987) 2038-2041
27. Green M.R. Pre-mRNA splicing. Annu. Rev. Genet. 20 (1986) 671-708
28. Shinnick T.M., Lerner R.A., and Sutcliffe J.G. Nucleotide sequence of Moloney murine leukaemia virus. Nature 293 (1981) 543-548
29. Johann S.V., van Zeijl M., Cekleniak J., and O'Hara B. Definition of a domain of GLVR1 which is necessary for infection by gibbon ape leukemia virus and which is highly polymorphic between species. J. Virol. 67 (1993) 6733-6736
30. Delassus S., Sonigo P., and Wain-Hobson S. Genetic organization of gibbon ape leukemia virus. Virology 173 (1989) 205-213
31. Bouck J., Fu X.D., Skalka A.M., and Katz R.A. Genetic selection for balanced retroviral splicing: novel regulation involving the second step can be mediated by transitions in the polypyrimidine tract. Mol. Cell Biol. 15 (1995) 2663-2671
32. van Santen V.L., and Spritz R.A. mRNA precursor splicing in vivo: sequence requirements determined by deletion analysis of an intervening sequence. Proc. Natl Acad. Sci. USA 82 (1985) 2885-2889
33. Coolidge C.J., Seely R.J., and Patton J.G. Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucl. Acids Res. 25 (1997) 888-896
34. Roscigno R.F., Weiner M., and Garcia-Blanco M.A. A mutational analysis of the polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing. J. Biol. Chem. 268 (1993) 11222-11229
35. Zamore P.D., Patton J.G., and Green M.R. Cloning and domain structure of the mammalian splicing factor U2AF. Nature 355 (1992) 609-614
36. Adams M.D., Rudner D.Z., and Rio D.C. Biochemistry and regulation of pre-mRNA splicing. Curr. Opin. Cell Biol. 8 (1996) 331-339
37. Amendt B.A., Si Z.H., and Stoltzfus C.M. Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors. Mol. Cell Biol. 15 (1995) 4606-4615
38. Arrigo S., and Beemon K. Regulation of Rous sarcoma virus RNA splicing and stability. Mol. Cell Biol. 8 (1988) 4858-4867
39. Staffa A., and Cochrane A. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol. Cell Biol. 15 (1995) 4597-4605
40. Cullen B.R. Nuclear mRNA export: insights from virology. Trends Biochem. Sci. 28 (2003) 419-424
41. Ernst R.K., Bray M., Rekosh D., and Hammarskjold M.L. A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA. Mol. Cell Biol. 17 (1997) 135-144
42. Saavedra C., Felber B., and Izaurralde E. The simian retrovirus-1 constitutive transport element, unlike the HIV-1 RRE, uses factors required for cellular mRNA export. Curr. Biol. 7 (1997) 619-628
43. Malim M.H., Hauber J., Le S.Y., Maizel J.V., and Cullen B.R. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338 (1989) 254-257
44. Kornblihtt A.R., de la Mata M., Fededa J.P., Munoz M.J., and Nogues G. Multiple links between transcription and splicing. Rna 10 (2004) 1489-1498
45. Cramer P., Pesce C.G., Baralle F.E., and Kornblihtt A.R. Functional association between promoter structure and transcript alternative splicing. Proc. Natl Acad. Sci. USA 94 (1997) 11456-11460
46. Nogues G., Kadener S., Cramer P., Bentley D., and Kornblihtt A.R. Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 277 (2002) 43110-43114
47. Auboeuf D., Dowhan D.H., Dutertre M., Martin N., Berget S.M., and O'Malley B.W. A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts. Mol. Cell Biol. 25 (2005) 5307-5316
48. Trubetskoy A.M., Okenquist S.A., and Lenz J. R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs. J. Virol. 73 (1999) 3477-3483
49. Miller A.D., Garcia J.V., von Suhr N., Lynch C.M., Wilson C., and Eiden M.V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65 (1991) 2220-2224
50. Solly S.K., Trajcevski S., Frisen C., Holzer G.W., Nelson E., Clerc B., et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 10 (2003) 30-39
51. Tai C.K., Wang W.J., Chen T.C., and Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 12 (2005) 842-851
52. Hiraoka K., Kimura T., Logg C.R., and Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin. Cancer Res. 12 (2006) 7108-7116
53. Metzl C., Mischek D., Salmons B., Gunzburg W.H., Renner M., and Portsmouth D. Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J. Virol. 80 (2006) 7070-7078
54. Qiao J., Moreno J., Sanchez-Perez L., Kottke T., Thompson J., Caruso M., et al. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther. 13 (2006) 1457-1470
55. Wang W.J., Tai C.K., Kasahara N., and Chen T.C. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther. 14 (2003) 117-127
56. Kikuchi E., Menendez S., Ozu C., Ohori M., Cordon-Cardo C., Logg C.R., et al. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther. 14 (2007) 279-286
57. Donahue R.E., Kessler S.W., Bodine D., McDonagh K., Dunbar C., Goodman S., et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Expt. Med. 176 (1992) 1125-1135
58. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
59. Moloney J.B. The rodent leukemias: virus-induced murine leukemias. Annu. Rev. Med. 15 (1964) 383-392
60. Klein E., and Klein G. Antibody response and leukemia development in mice inoculated neonatally with the Moloney virus. Cancer Res. 25 (1965) 851-854
61. Cornetta K., Moen R.C., Culver K., Morgan R.A., McLachlin J.R., Sturm S., et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1 (1990) 15-30
62. Cornetta K., Morgan R.A., Gillio A., Sturm S., Baltrucki L., O'Reilly R., and Anderson W.F. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene Ther. 2 (1991) 215-219
63. Logg C.R., and Kasahara N. Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. Methods Mol. Biol. 246 (2004) 499-525
64. Telesnitsky A., Blain S., and Goff S.P. Assays for retroviral reverse transcriptase. Methods Enzymol. 262 (1995) 347-362